Potential neuroprotective effectsof epigallocatechin gallateon behavioral impairmentsin normal and alzheimer's rats chemically induced by aluminum oxide nanoparticles
International Journal of Development Research
Potential neuroprotective effectsof epigallocatechin gallateon behavioral impairmentsin normal and alzheimer's rats chemically induced by aluminum oxide nanoparticles
Received 14th January, 2019; Received in revised form 26th February, 2019; Accepted 08th March, 2019l Published online 29th April, 2019
Copyright © 2019, Mohy eldinAbd el fattah et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Alzheimer’s disease (AD) is the most common cause of dementia. Epigallocatechin gallate (EGCG), it is most abundant polyphenolin green tea. In addition, it is the most potent neuroprotective compound in green tea. The aim of this study was to evaluate the possible neuroprotective effects of EGCG on behavioral impairments in normal and Alzheimer'srats induced by Aluminum oxide nanoparticles. Forty-eight groups of rats were divided into 8 groups, 6 rats each; Group (1) normal control, received 1ml saline 0.9% orally daily throughout the experiment. Group (2) AI2O3NPS-treated rats, received only AI2O3NPS. alonein a dose 50 mg/ kg b.wintraperitoneally (i.p), for five weeks. Group (3) received EGCG alone in a dose of 5 mg/kg b.w. i.v every day for five weeks. Group (4) received EGCG alone in a dose of 10 mg/kg b.w. i.v every day for five weeks. Group (5) received Rivastigmine (Exelon) in a dose of 0.3 mg/kg b.w. orally for five weeks. Group (6) received AI2O3NPS in a dose of 50 mg/kg (i.p), for five weeks followed by simultaneous administration of EGCG in of a dose 5 mg/kg b.w. i.v every day for five weeks. Group (7) received AI2O3NPS in a dose of 50 mg/kg b.w(i.p), for five weeks followed by simultaneous administration of EGCG in a dose of 10 mg/kg b.w. i.v every day for five weeks. Group (8) received AI2O3NPS in a dose of 50 mg/kg b.w (i.p), for five weeks followed by simultaneous administration of Rivastigmine (Exelon) in a dose of 0.3 mg/kg b.w. orally for five weeks. The study revealed that, brain neurological damage characterizing induction of AD as indicated by histopathological changes in the brain; in addition to increase in learning time and trials number in the behavioural tests. Hippocampus neuronal degeneration and pyknosis were detected. Our results showed that, EGCG is more effective in minimizing the hazards of Aluminum oxide nanoparticles-induced AD than Rivastigmine (Exelon) on behavioral impairments in Alzheimer's disease rats induced by Aluminum oxide nanoparticles.